Healthcare
Live Price
Offline$26.06
-0.33% today
1Y Change
+25.19%
Window
Jun 30, 2025 → Jun 24, 2026
Coverage: 247 bars · Jun 30, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Genmab A/S (GMAB) is a Healthcare stock with a market cap of $16.28B and listed on NASDAQ. The stock last traded around $26.05 and up 25.2% across the available one-year price window (Jun 30, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of -82.7%, EPS growth of -87.3%, a dividend yield of 0.0%. What stands out right now is revenue -82.7%, EPS -87.3%, free cash flow -84.8% with operating margin 36.7% and ROIC 50.3%. Valuation is more restrained than many high-expectation growth names at P/E 4.2 and price/sales 0.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GMAB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
GMAB is 6.52 pts ahead over the shared 1Y window.
GMAB had 23.38 pts deeper max drawdown than SPY.
GMAB beat SPY in 1 of 2 calendar years shown and trailed in 1.
GMAB
+25.19%
Normalized return
SPY
+18.68%
S&P 500
Excess Return
+6.52 pts
Relative to SPY
GMAB Max Drawdown
-32.51%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for GMAB and SPY.
| Year | GMAB | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -18.71% | +6.71% | -25.42 pts | SPY |
| 2025 | +52.42% | +11.19% | +41.23 pts | GMAB |
Unable to load analyst forecasts.
Timed out loading forecasts for GMAB
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.